Mintz advised the placement agents in the $145 million private placement of First Tracks Biotherapeutics’ common stock, which included $80 million of common stock sold by First Tracks Biotherapeutics and $65 million of common stock sold by a selling stockholder. The private placement was in connection with the spin-off of First Tracks Biotherapeutics from AnaptysBio.

Leerink Partners, Barclays, and UBS Investment Bank acted as placement agents.

The Mintz capital markets team included William Hicks, John Rudy, Nishant Dharia, Hannah Karraker, and Michelle St Francis. Members of the Mintz team are based in the Boston, New York and San Diego offices.